Author

Peter Wengenmayer

Institution: CureVac (Germany)

Observed institution: CureVac (Germany)

OpenAlex ID: A5072276143

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma

2025 · Thomas Eigentler, Ioannis Thomas, et al. · Journal for ImmunoTherapy of Cancer · 11

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity

2024 · Olaf-Oliver Wolz, Dominik Vahrenhorst, et al. · Vaccines · 3

784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion

2022 · Marina Gonzalez, Peter Wengenmayer, et al. · Journal for ImmunoTherapy of Cancer

473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial

2021 · Paula Codó, Thomas Eigentler, et al. · Journal for ImmunoTherapy of Cancer

Works count: 4

Citation count: 14

H-index: 2

I10-index: 1